{
    "id": "dbpedia_4740_3",
    "rank": 75,
    "data": {
        "url": "https://www.greenlight.guru/blog/top-100-medical-device-companies",
        "read_more_link": "",
        "language": "en",
        "title": "Top 100 Medical Device Companies in the World (Free Chart Included)",
        "top_image": "https://www.greenlight.guru/hubfs/Top%20100%20Medical%20Device%20Companies.png",
        "meta_img": "https://www.greenlight.guru/hubfs/Top%20100%20Medical%20Device%20Companies.png",
        "images": [
            "https://no-cache.hubspot.com/cta/default/495719/5690feaf-bb12-4916-b5b3-d0c4402310ce.png",
            "https://www.greenlight.guru/hubfs/Quality_Icon_Only-01%201.png",
            "https://www.greenlight.guru/hubfs/Clincal_Icon_Only-01%202.png",
            "https://www.greenlight.guru/hubfs/1c80449f28c128fe6ddd899d6119875b-1.png",
            "https://www.greenlight.guru/hubfs/Quality_Navigation_Image-03.png",
            "https://www.greenlight.guru/hubfs/Quality_Icon_Gradient%202.png",
            "https://www.greenlight.guru/hubfs/670c8460eeee3f953fd4312fef0a4ca3-1.png",
            "https://www.greenlight.guru/hubfs/Navigation_EDC.png",
            "https://www.greenlight.guru/hubfs/Clincial_Icon_Gradient-01%201.png",
            "https://www.greenlight.guru/hs-fs/hubfs/BestQMS-book-mockup-01.webp?length=10&name=BestQMS-book-mockup-01.webp 10w, https://www.greenlight.guru/hs-fs/hubfs/BestQMS-book-mockup-01.webp?length=1000&name=BestQMS-book-mockup-01.webp 1000w",
            "https://no-cache.hubspot.com/cta/default/495719/df8edfba-9502-444a-8575-76dad17db2c7.png",
            "https://no-cache.hubspot.com/cta/default/495719/df8edfba-9502-444a-8575-76dad17db2c7.png",
            "https://blog.greenlight.guru/hubfs/Top%20100%20Medical%20Device%20Companies.png",
            "https://no-cache.hubspot.com/cta/default/495719/92a82985-63e9-4a73-874a-1e11c6accff8.png",
            "https://www.greenlight.guru/hs-fs/hubfs/images/home/Greenlight-Guru-Quality-Management-Software.png?width=649&name=Greenlight-Guru-Quality-Management-Software.png",
            "https://www.greenlight.guru/hs-fs/hubfs/Imported_Blog_Media/Top%20100%20Medical%20Device%20Companies.jpg?width=250&name=Top%20100%20Medical%20Device%20Companies.jpg",
            "https://www.greenlight.guru/hubfs/2022%20Website%20Redesign/Images/ISO%209001_2015.png",
            "https://www.greenlight.guru/hubfs/2022%20Website%20Redesign/Images/ISO_IEC%2027001_2013.png",
            "https://www.greenlight.guru/hubfs/2022%20Website%20Redesign/Images/21972-312_SOC_NonCPA.png",
            "https://www.greenlight.guru/hubfs/GG22_theme-files/logos/greenlight-guru-logomark.svg",
            "https://googleads.g.doubleclick.net/pagead/viewthroughconversion/971980047/?guid=ON&script=0"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "holds a Project"
        ],
        "publish_date": null,
        "summary": "",
        "meta_description": "We've gathered the ultimate list of the top 100 medical device companies including their total revenue, market cap, and R&D spend.",
        "meta_lang": "en",
        "meta_favicon": "https://www.greenlight.guru/hubfs/images/greenlight-guru/greenlight-guru-favicon.png?v=21",
        "meta_site_name": "",
        "canonical_link": "https://www.greenlight.guru/blog/top-100-medical-device-companies",
        "text": "Have you ever wondered about the biggest medical device companies in the world?\n\nMaybe you're looking for a publicly traded medical device, medical instrument, or biotechnology company that might want to acquire your company or license your research, or perhaps you're looking for a publicly traded medical device company to invest in?\n\nIn this exclusive piece of content, we're bringing you a list of the top 100 medical device companies from around the world. This list is intended to help you answer important questions like:\n\nWhat are the top 100 medical device companies in the world by market cap?\n\nWhich medical device companies spend the most money on R&D?\n\nWhich medical device companies employ the most people around the world?\n\nWhich medical device companies bring in the most revenue?\n\nHow We Researched the Top 100 Medical Device Companies\n\nTo gather the information, we researched the most recent annual report from each of the 100 medical device companies. Publicly traded companies must release their financial data, including total revenue and total R&D spending, in annual and quarterly reports. These companies end their fiscal year at different times, and the reports used in compiling this list were published on 03/30/2019, 09/30/2018, or 12/31/2018.\n\nThe market caps, a measure of the value of all stocks available for that company, are current as of March 2020. Companies are often classified in terms of their market cap as follows:\n\nMega-cap medical device companies have a market cap in excess of $200 billion.\n\nLarge-cap medical device companies have a market cap of $10 billion to $200 billion.\n\nMid-cap medical device companies have a market cap of $2 billion to $10 billion.\n\nSmall-cap medical device companies have a market cap of $300 million to $2 billion.\n\nMicro-cap medical device companies have a market cap of $50 million to $300 million.\n\nFor complete financial information on these medical device companies, navigate to the investor information in each of the site links, and download the annual report. You'll be able to learn more about your chosen company, including expenses, profits, and cash flow statements.\n\nHow to Use This Research on Medical Device Companies\n\nYou can use this research to develop a broader view of the global medical devices marketplace and get to know the biggest medical device companies in the industry. This information can help you:\n\nDiscover companies developing technology that you may want to work on or that you could benefit from\n\nFind a strategic partner or a larger firm that may want to acquire your business or research\n\nEvaluate the amount of revenue generated globally by medical device sales each year, especially by the industry giants that control large portions of the market\n\nLet’s take a look at the top 100 medical device companies in 2020:\n\nCOMPANY NAME STOCK TOTAL REVENUE MARKET CAP R&D SPEND EMPLOYEE SIZE Johnson & Johnson JNJ $82.06B $368.91B $11.4B 132,200 Novartis AG NVS $49.49B $199.09B $8.1B 103,941 Abbott Laboratories ABT $30.6B $143.91B $2.3B 103,000 Medtronic PLC MDT $30.56B $137.53B $2.33B 101,000 Baxter International BAX $11.1B $129B $655M 50,000 Danaher Corporation DHR $19.89B $104.92B $1.23B 71,000 General Electric GE $95.21B $97.98B $4.16B 205,000 3M Company MMM $32.8B $87.99B $1.8B 93,516 Siemens Healthineers SHL €14.5B $87.87B €1.32B 52,000 Stryker Corporation SYK $13.6B $73.87B $856M 36,000 Becton, Dickinson & Company BDX $17.3B $66.52B $1.06B 70,093 Intuitive Surgical Inc. ISRG $3.08B $64.84B $418M 5,527 Allergan PLC AGN $15.78B $63.77B $2.22B 16,900 Hoya Corp 7741 ¥565.81B JPY ¥3.49T JPY ¥28B JPY 34000 Boston Scientific Corp BSX $9.82B $55.43B $1.13B 32,000 Edwards LifeSciences Corp EW $3.8B $44.53B $646M 13,000 Koninklijke Philips N.V. PHG €19.5B €38.63B €1.76B 80,495 Draegerwerk AG & Co KGaA ETR: DRW3 €2.59B €30.16B €780.75 1,417 Coloplast A/S CLPBF $17.93B DKK $29.29B USD $692M DKK 11,821 Zimmer Biomet Holdings ZBH $7.93B $28.74B $388M 19,000 Fresenius Medical Care AG & Co. KGaA FMS €16.54B €25.67B €134M 112,658 Olympus Corporation 7733 ¥793.9 B $25.18B ¥84,570M 35,124 Terumo Corporation 4543 ¥587.8B $25.09B ¥41.34M 23,319 ResMed Inc. RMD $2.6B $24.4B $180.6M 7,240 Smith & Nephew PLC SNN $4.9B $20.21B $246M 16,000 Align Technology ALGN $1.9B $18.13B $128.9M 11,660 The Cooper Companies Inc. COO $2.53B $16.49B $75M 12,000 Teleflex Inc. TFX $2.44B $16.39B $106.2 15,200 Cardinal Health Inc. CAH $145.5B $15.76B N/A 49,500 Straumann Holding AG STMN.SW CHF 1.59B $15.09B N/A 7,590 Steris PLC STE $2.78B $13.86B $63.03M 12,000 Hologic Inc. HOLX $3.21B $12.85B $218.7M 6,252 Waters Corporation WAT $2.41B $12.6B $143M 7,200 West Pharmaceutical Services WST $1.72B $11.55B $40.3M 7,700 Varian Medical Systems Inc. VAR $2.61B $11.47B $246M 10,062 Dentsply Sirona Inc. XRAY $3.98B $11.04B $160.5M 16,400 Masimo Corporation MASI $858M $9.5B $76.9M 1,500 Sartorius Stedim Biotech S.A. SUVPF €1.93B €6.87B €95.6M 9,016 Fisher & Paykel Healthcare Co. Ltd. FPH $1.07B NZD $15.28B NZD $428.2M NZD 4,500 Cochlear Limited COH $1.24B AUD $12B AUD $184.4M AUD 4,000 ABIOMED Inc. ABMD $769M $6.99B $94M 1,350 Asahi Intecc Co., Ltd. 7747 ¥50.12B ¥734.13B ¥12.3B 7810 Hill-Rom Holdings Inc. HRC $2.91B $6.74B $139.5M 10,000 Amplifon SpA AMPPF €1.37B €5.465B None 16,000 Haemonetics Corporation HAE $967M $5.56B $35.7M 3,216 Shandong Weigao Group Medical Polymer 1066 ¥8.8M $5.02B ¥311.6M 9,562 Insulet Corporation PODD $738M $4.92B $129.7M 1350 Globus Medical Inc. GMED $785.4M $4.7B $60M 1,800 Getinge AB GNGBF SEK 24.2B $4.68B SEK 1.25B 10,515 Tandem Diabetes Care Inc. TNDM $183.9M $4.64B $8.7M 643 Integra LifeSciences Holdings Corporation IART $1.47B $4.44B $77.9M 4,500 Inogen Inc. INGN $361.9M $4.311B $3.62M 1020 Nevro Corp NVRO $387.2M $4.25B $48.45M 804 ICU Medical Inc. ICUI $1.4B $4.15B $52.8M 8,100 Wright Medical Group N.V. WMGI $836M $3.91B $59.1M 2,894 MicroPort Scientific Corporation 0853 $669.49M $3.828B $104.8M 5,000 NuVasive NUVA $1.1B $3.42B $61M 2,600 CONMED Corporation CNMD $859.63M $2.78B $42.1M 3,100 Gerresheimer AG GXI €1.39B €2.13B € 0.00 9,872 Merit Medical Systems MMSI $882.7M $2.04B $59.53M 5,783 Prestige Brands Holdings PBH $975.77M $1.93B None 530 Ypsomed Holding AG YPSN CHF453.8M CHF1.78B CHF 41.9M 1,604 Glaukos Corporation GKOS $236.98M $1.61B $68.3M 600 Atricure Inc. ATRC $201.6M $1.57B $34.7M 620 STAAR Surgical Company STAA $150.2M $1.42B $25.2M 475 Cardiovascular Systems Inc. CSII $217M $1.39B $26.8M 652 Arjo AB ARJOB 8.21B SEK 13.89B SEK 201M SEK 6123 Atrion Corporation ATRI $152.4M $1.22B $5.5M 570 Paul Hartmann AG PLHNF €2.12B €1.1B €478.86M 11,027 Luminex Corp LMNX $315.8M $1.19B $47.2M 1141 Mesa Laboratories Inc. MLAB $103.13M $1.1B $3.5M 366 CryoLife Inc. CRY $262.8M $0.99B $23.6M 1,100 Natus Medical Inc. BABY $495.1M $940M $58.73M 1,484 Biotage AB BIOT $1.1B SEK $7.739B SEK $78.6M SEK 464 Intersect ENT Inc. XENT $108.47M $730M $19.26M 393 Orthofix International N.V. OFIX $453M $700M $33.21M 954 Advanced Medical Solutions Group AMS £102.6M 545.82B £3.07M 600 Consort Medical CSRT £305.1M £502.1M £7.9M 2,000 LeMaitre Vascular Inc. LMAT $105.56M $580M $8.1M 483 AxoGen Inc. AXGN $106.71M $470M $17.5M 297 AngioDynamics Inc. ANGO $344.28M $440M $25.45M 1,145 Owens & Minor Inc. OMI $9.83B $380M N/A 17,900 OraSure Technologies Inc. OSUR $181.74M $380M $16.3M 347 Cutera Inc. CUTR $162.7M $330M $14.3M 402 Utah Medical Products Inc. UTMD $41.9M $320M $454K 173 RTI Surgical Inc. RTIX $290.9M $280M $14.4M 891 ViewRay Inc. VRAY $81M $280M $4.01M 221 BioLife Solutions Inc. BLFS $19.7M $280M $315K 54 Invacare Corporation IVC $972.34M $270M $17.3M 4,200 SeaSpine Holdings Corporation SPNE $143M $270M $3.2M 386 IRadimed Corporation IRMD $30.4M $270M $1.5M 95 Tristel PLC TSTL £26.17M £193.6M None 111 GenMark Diagnostics Inc. GNMK $70.75M $200M $27.93M 477 Nemaura Medical Inc. NMRD None $159.2M $2.29B 10 FONAR Corporation FONR $81.5M $130M $1.7M 525 Harvard BioScience Inc. HBIO $120.77M $110M $11M 547 China Grand Pharmaceutical and Healthcare Holdings Private $5.95B HKD $310.8M HKD $137.4M HKD 8,006 TransEnterix Inc. TRXC $24.1M $29.43M $21.8M 189 Endologix Inc. ELGX $156.4M $20M $20.7M 528 B. Braun Melsungen AG Private €6.9 B Privately Held €318M 62,855\n\nWith our exclusive research, you'll be able to:\n\nReview the largest medical device companies in the world by market cap\n\nDevelop a broader view of the medical devices global marketplace, the biggest players in the industry and the products and innovations making the biggest impacts today\n\nDiscover companies developing technology that you may want to work on, or that you could benefit from\n\nFind a strategic partner or a larger firm that may want to acquire your business or research\n\nAppreciate the amount of revenue generated globally by medical device sales each year, especially by the industry giants that control huge amounts of market share\n\nGet links to each company's website where you can look up additional product information along with financial data and annual reports.\n\nFree Bonus Giveaway: Click here to download our exclusive chart of the top 100 medical device companies in the world.\n\nTop 100 Medical Device Companies in 2020\n\nJOHNSON & JOHNSON (NYSE: JNJ)\n\nTotal Revenue: $82.06B USD\n\nMarket Cap: $368.91B USD\n\nR&D Spend: $11.4B USD\n\nEmployee Size: 132,200\n\nWebsite: http://www.jnj.com/\n\nJohnson & Johnson is a medical device, pharmaceutical, and consumer packaged-goods company founded in 1886. Headquartered in New Brunswick, New Jersey, the corporation operates 250 subsidiary companies in 60 countries and sells products in 175 countries. It is also the largest independent biotech firm in the world by market cap.\n\nNOVARTIS AG (NYSE: NVS)\n\nTotal Revenue: $49.49B USD\n\nMarket Cap: $199.09B USD\n\nR&D Spend: $8.1B USD\n\nEmployee Size: 103,941\n\nWebsite: https://www.novartis.com\n\nNovartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies by both market capitalization and sales, and it is the third-largest Swiss company by revenue. The company’s several divisions design, manufacture, and sell medical devices across a wide range of applications, but the company might be best known for its Alcon vision, which focuses on eye-care products for cataracts, glaucoma, and refractive surgery and on disposable vision-corrective products.\n\nABBOTT LABORATORIES (NYSE: ABT)\n\nTotal Revenue:$30.6B USD\n\nMarket Cap: $143.91B USD\n\nR&D Spend: $2.3B USD\n\nEmployee Size: 103,000\n\nWebsite: http://www.abbott.com\n\nAbbott Laboratories is an American health care company with headquarters in Abbot Park,Ilinois. The massive firm is operated in seven industrial divisions – Abbott Diabetes Care, Abbott Diagnostics Division, Abbott Molecular Diagnostics, Abbott Nutrition International, Abbott Point-of-care, Abbott Vascular Division, and Established Pharmaceuticals Division. A truly global company, Abbott does business in over 150 countries around the world.\n\nMEDTRONIC PLC (NYSE: MDT)\n\nTotal Revenue: $30.56B USD\n\nMarket Cap: $137.53B USD\n\nR&D Spend: $2.33B USD\n\nEmployee Size: 101,000\n\nWebsite: https://www.medtronic.com/\n\nMedtronic PLC is a medical device company. Its headquarters are in Dublin, Ireland. Its operational headquarters are in Fridley, Minnesota. Medtronic is among the world's largest medical equipment development companies. Its extensive product line includes patient care and monitoring accessories of all kinds; general surgical equipment; and medical devices for cardiovascular, diabetic, and neurological applications.\n\nBAXTER INTERNATIONAL (NYSE: BAX)\n\nTotal Revenue: $11.1B USD\n\nMarket Cap: $129B USD\n\nR&D Spend: $655M USD\n\nEmployee Size: 50,000\n\nWebsite: https://www.baxter.com/\n\nBaxter International Inc. provides a portfolio of health care products. The company operates throughout North America and South America, Europe, Africa, and the Middle East, and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.\n\nDANAHER CORPORATION (NYSE: DHR)\n\nTotal Revenue: $19.89B USD\n\nMarket Cap: $104.92B USD\n\nR&D Spend: $1.23B USD\n\nEmployee Size: 71,000\n\nWebsite: http://www.danaher.com/\n\nThe Danaher Corporation is a globally diversified conglomerate headquartered in Washington, D.C. Danaher is number 160 on the Fortune 500 list. Its products are concentrated in the fields of design, manufacturing, and marketing of industrial, health care, and consumer products. It operates in four segments: environmental and applied solutions, life sciences, diagnostics, and dental.\n\nGENERAL ELECTRIC (NYSE: GE)\n\nTotal Revenue: $95.21B USD\n\nMarket Cap: $97.98B USD\n\nR&D Spend: $4.16B USD\n\nEmployee Size: 205,000\n\nWebsite: https://www.ge.com/\n\nGE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. The company’s expertise in electrical systems has translated to industry-leading innovations in medical imaging and information technologies, diagnostics, patient monitoring, and manufacturing technologies. GE is one of the largest companies in the world by employee size, with 205,000 employees working around the world.\n\n3M COMPANY (NYSE: MMM)\n\nTotal Revenue: $32.8B USD\n\nMarket Cap: $87.99B USD\n\nR&D Spend: $1.8B USD\n\nEmployee Size: 93,516\n\nWebsite: https://www.3m.com/\n\nThe 3M Company, formerly known as the Minnesota Mining and Manufacturing Company, is an American multinational conglomerate corporation operating in the fields of industry, health care, and consumer goods. 3M’s innovative health care brands include Cavilon, Clarity, Coban, CodeFinder, FUTURO, Littmann, Peltor, Petrifilm, Tegaderm, and Unitek. The company builds medical devices, food-safety testing products, and health information systems.\n\nSIEMENS HEALTHINEERS (ETR: SHL)\n\nTotal Revenue: €14.5B EUR\n\nMarket Cap: $87.87B USD\n\nR&D Spend: €1.32B EUR\n\nEmployee Size: 52,000\n\nWebsite: https://www.healthcare.siemens.com/\n\nSiemens Healthineers is a medical technology company headquartered in Erlangen, Germany. The company was founded in 1847 in Berlin by Ernst Werner von Siemens. Siemens is enabling health care providers to expand precision medicine and improve the patient experience by digitizing health care. The company has 170 years of experience and 65,000 patents around the world.\n\nSTRYKER CORPORATION (NYSE: SYK)\n\nTotal Revenue: $13.6B USD\n\nMarket Cap: $73.87B USD\n\nR&D Spend: $856M USD\n\nEmployee Size: 36,000\n\nWebsite: http://www.stryker.com/\n\nStryker Corporation is a Fortune 500 medical technologies firm based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular, and spinal devices; and other medical device products used in a variety of medical specialties.\n\nBECTON, DICKINSON AND COMPANY (NYSE: BDX)\n\nTotal Revenue: $17.3B USD\n\nMarket Cap: $66.52B USD\n\nR&D Spend: $1.06B USD\n\nEmployee Size: 70,093\n\nWebsite: http://www.bd.com/\n\nBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments: BD Medical and BD Life Sciences. The company markets its products through independent distribution channels and sales representatives to health care institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.\n\nINTUITIVE SURGICAL INC. (NASDAQ: ISRG)\n\nTotal Revenue: $3.08B USD\n\nMarket Cap: $64.84B USD\n\nR&D Spend: $418 USD\n\nEmployee Size: 5,527\n\nWebsite: http://www.intuitivesurgical.com/\n\nIntuitive Surgical Inc. is a global technology leader in minimally invasive robotic-assisted surgery. The company's da Vinci Surgical System enables surgeons to operate in a minimally invasively way through a few small incisions while positioned at a nearby ergonomic console. The da Vinci System features a magnified 3D HD vision system with instruments that bend and rotate far greater than that possible by the human hand. As a result of this technology, da Vinci enables surgeons to operate with enhanced vision, precision, and control.\n\nALLERGAN PLC (NYSE: AGN)\n\nTotal Revenue: $15.78B USD\n\nMarket Cap: $63.77B USD\n\nR&D Spend: $2.22B USD\n\nEmployee Size: 16,900\n\nWebsite: https://www.allergan.com/\n\nAllergan PLC is a multinational company that produces branded drugs and performs pharmaceutical research and development. Allergan markets a portfolio of leading brands and best-in-class products for eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, anti-infective therapeutic categories, and the central nervous system. Allergan is an industry leader in Open Science, the company’s R&D model, which defines its approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry.\n\nHOYA CORPORATION (TYO: 7741)\n\nTotal Revenue: ¥565.81B JPY\n\nMarket Cap: ¥3.49T JPY\n\nR&D Spend: ¥28B JPY\n\nEmployee Size: 34,635\n\nWebsite: http://www.hoya.com/\n\nHoya Corporation is a Japanese medical technology company that manufactures a range of eyewear products. The company has a range of contacts and glasses created with wavefront technology for the health care market. Hoya also creates medical photonics and other products. The company is a Forbes Global 2,000 Technology Companies and acquired Pentax in 2007 for $1 billion USD.\n\nBOSTON SCIENTIFIC CORPORATION (NYSE: BSX)\n\nTotal Revenue: $9.82B USD\n\nMarket Cap: $55.43B USD\n\nR&D Spend: $1.13B USD\n\nEmployee Size: 32,000\n\nWebsite: http://www.bostonscientific.com/\n\nBoston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology, and gynecology.\n\nBoston Scientific is primarily known for the development of the Taxus stent, a drug-eluting stent, which is used to open clogged arteries.\n\nEDWARDS LIFESCIENCES CORP (NYSE: EW)\n\nTotal Revenue: $3.8B USD\n\nMarket Cap: $44.53B USD\n\nR&D Spend: $646M USD\n\nEmployee Size: 13,000\n\nWebsite: http://www.edwards.com/\n\nEdwards Lifesciences Corporation, incorporated on September 10, 1999, is a manufacturer of heart-valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The company is globally engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include the United States, Europe, Japan, and the rest of the world. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy, and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting.\n\nKONINKLIJKE PHILIPS N.V. (AEX: PHIA)\n\nTotal Revenue: €19.5B EUR\n\nMarket Cap: €38.63B EUR\n\nR&D Spend: €1.88B EUR\n\nEmployee Size: 80,495\n\nWebsite: https://www.philips.com/global\n\nKoninklijke Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum, from healthy living and prevention to diagnosis, treatment, and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring, and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated sales of EUR 19.5 billion in 2019 and employs approximately 80,495 employees, with sales and services in more than 100 countries.\n\nDRAEGERWERK AG & CO KGAA (ETRL: DRW3)\n\nTotal Revenue: €2.59B EUR\n\nMarket Cap: €30.16B EUR\n\nR&D Spend: €780.75\n\nEmployee Size: 173\n\nWebsite: https://www.draeger.com\n\nDraegerwerk AG & CO KGAA is a German medical device company that makes breathing and protection equipment as well as systems for gas detection, analysis systems, and noninvasive patient-monitoring technologies. The company has sales and subsidiaries in 50 countries and is represented worldwide.\n\nCOLOPLAST A/S (CPH: COLO-B)\n\nTotal Revenue: $17.93B DKK\n\nMarket Cap: $29.29B USD\n\nR&D Spend: $692M DKK\n\nEmployee Size: 11,821\n\nWebsite: https://www.coloplast.com/\n\nColoplast A/S is a Denmark-based company active within the health care sector. It is engaged in the development, marketing, and sale of intimate health care products and services, targeting people with diseases of a private or personal nature. Its operations are divided into four business areas: Ostomy Care, offering products for people whose intestinal outlet has been rerouted through the abdominal wall; Continence Care, offering products for people suffering from diseases of and damage to the urinary system; Urology Care, offering products for people suffering from diseases of and damage to the kidneys, the urinary system, or the male reproductive system; and Wound & Skin Care, offering products for the treatment of chronic wounds, as well as skin care products. The company supplies products to hospitals, institutions, wholesalers, and pharmacies.\n\nZIMMER BIOMET HOLDINGS (NYSE: ZBH)\n\nTotal Revenue: $7.93B USD\n\nMarket Cap: $28.74B USD\n\nR&D Spend: $388M USD\n\nEmployee Size: 19,000\n\nWebsite: http://www.zimmerbiomet.com/\n\nZimmer Biomet was founded in 1927 to produce aluminum splints and is part of the medical devices business cluster in Warsaw, Indiana. The company’s core business includes the design, development, and manufacturing of orthopedic products – knee, hip, shoulder, elbow, and ankle artificial joints and prosthetic dental devices. Zimmer operates in 40+ countries around the world and has grown largely through acquisitions, most recently that of Biomet Inc. in 2014 for $13.4 billion.\n\nFRESENIUS MEDICAL CARE AG & CO. KGAA (NYSE: FMS)\n\nTotal Revenue: €16.54B EUR\n\nMarket Cap: €25.67B EUR\n\nR&D Spend: €134M EUR\n\nEmployee Size: 112,658\n\nWebsite: https://fmcna.com\n\nFresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for patients hospitalized with end-stage renal disease (ESRD) and for patients suffering from acute kidney failure.\n\nOLYMPUS CORPORATION (TYO: 7733)\n\nTotal Revenue: ¥793.9 B JPY\n\nMarket Cap: $25.18B USD\n\nR&D Spend: ¥84.57B JPY\n\nEmployee Size: 35,124\n\nWebsite: http://www.olympus-global.com/\n\nOlympus Corporation is a Japanese manufacturer of optics and reprography products. Olympus was established on October 12, 1919, and initially specialized in microscopes and thermometers. Today, the company earns the majority of its annual revenue through its medical device business, with the remaining coming from its scientific solutions and imaging departments. Olympus primarily manufactures and sells endotherapy devices, surgical devices, and endoscopes.\n\nTERUMO CORPORATION (TYO: 4543)\n\nTotal Revenue: ¥587.8B JPY\n\nMarket Cap: $25.09B USD\n\nR&D Spend: ¥41.34M JPY\n\nEmployee Size: 23,319\n\nWebsite: http://www.terumomedical.com\n\nDr. Shibasaburo Kitasato and other physicians founded Terumo in 1921, when importation of medical thermometers ceased in the aftermath of World War I, spurring the need to manufacture the instruments domestically. Over the years, Terumo has provided new value by grappling with health care issues in areas such as infection control, prevention of medical errors, the demand for minimally invasive treatments, and improvements in both medical cost efficiency and patient quality of life (QOL). The Terumo Group now conducts business in over 160 nations, expanding the concept of “society” to embrace a global perspective.\n\nRESMED INC. (NYSE: RMD)\n\nTotal Revenue: $2.6B USD\n\nMarket Cap: $24.4B USD\n\nR&D Spend: $180.6M USD\n\nEmployee Size: 7,240\n\nWebsite: http://www.resmed.com/\n\nResMed Inc., incorporated on March 31, 1994, is a holding company. The company is engaged in the development, manufacturing, distribution, and marketing of medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders, including sleep-disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease, and other diseases.\n\nSMITH & NEPHEW PLC (NYSE: SNN)\n\nTotal Revenue: $4.9B USD\n\nMarket Cap: $20.21B USD\n\nR&D Spend: $246M USD\n\nEmployee Size: 16,000\n\nWebsite: http://www.smith-nephew.com/\n\nSmith & Nephew PLC has a history dating back 160 years to the family enterprise of Thomas James Smith, who opened a small pharmacy in Hull, England, in 1856. Upon his death, in 1896, his nephew, Horatio Nelson Smith, took over the management of the business. A few days after the declaration of World War I, in 1914, Horatio Nelson Smith met with an envoy of the French president in London. Smith & Nephew PLC was awarded a contract to supply £350,000 of surgical and field dressings, to be delivered in five months.\n\nToday, the company has grown rapidly through acquisitions and is listed in the FTSE-100, an index fund comprising the largest 100 companies on the London Stock Exchange by market cap.\n\nALIGN TECHNOLOGY (NASDAQ: ALGN)\n\nTotal Revenue: $1.9B USD\n\nMarket Cap: $18.13B USD\n\nR&D Spend: $128.9M USD\n\nEmployee Size: 11,600\n\nWebsite: http://www.aligntech.com/\n\nAlign Technology is a manufacturer of 3D digital scanners and clear aligners used in orthodontics. It is headquartered in San Jose, California. It manufactures the aligners in Juarez, Mexico, and its scanners in Israel. In 1999, Align Technology pioneered the invisible orthodontics market with the introduction of the Invisalign system and by 2001 had manufactured 1 million unique clear aligners. The Invisalign system is offered to adult and teenage patients by Invisalign-trained doctors in more than 90 countries worldwide.\n\nTHE COOPER COMPANIES INC. (NYSE: COO)\n\nTotal Revenue: $2.53B USD\n\nMarket Cap: $16.49B USD\n\nR&D Spend: $75M USD\n\nEmployee Size: 12,000\n\nWebsite: http://www.coopercos.com/\n\nThe Cooper Companies Inc., incorporated on March 4, 1980, is a global medical device company. The company operates through two business units: CooperVision Inc. and CooperSurgical Inc. CooperVision offers soft contact lenses for the vision-correction market. CooperSurgical offers an array of products and services focused on advancing the health of families through a portfolio of products and services geared towards women's health, fertility, and diagnostics.\n\nCooperVision develops, manufactures, and markets a range of single-use, two-week, and monthly contact lenses, featuring various materials and optics. CooperVision's products are designed to solve vision challenges, such as astigmatism, presbyopia, ocular dryness, and eye fatigue, with a collection of spherical, toric, and multifocal contact lenses.\n\nTELEFLEX INC. (NYSE: TFX)\n\nTotal Revenue: $2.44B USD\n\nMarket Cap: $16.39B USD\n\nR&D Spend: $106.2 USD\n\nEmployee Size: 15,200\n\nWebsite: http://www.teleflex.com/\n\nTeleflex Inc., incorporated on June 25, 1943, is a provider of medical technology products. The company primarily designs, develops, manufactures, and supplies single-use medical devices used by hospitals and health care providers for common diagnostic and therapeutic procedures in critical care and surgical applications. The company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, Middle East, Africa (EMEA); Asia; and Original Equipment Manufacturer and Development Services.\n\nCARDINAL HEALTH INC. (NYSE: CAH)\n\nTotal Revenue: $145.5B USD\n\nMarket Cap: $15.76B USD\n\nR&D Spend: None\n\nEmployee Size: 49,500\n\nWebsite: https://www.cardinalhealth.com/\n\nCardinal Health offers distribution, inventory management, data reporting, new product launch support, and charge-back administration services to pharmaceutical manufacturers; pharmacy and medication therapy management, and patient outcomes services to hospitals, other health care providers, and payers; and consulting, patient support, and other services to pharmaceutical manufacturers and health care providers. Cardinal Health Inc. was founded in 1979 and is headquartered in Dublin, Ohio.\n\nSTRAUMANN HOLDING AG (STMN.SW)\n\nTotal Revenue: 1.59B CHF\n\nMarket Cap: $15.09B\n\nR&D Spend: None\n\nEmployee Size: 7,590\n\nWebsite: https://www.straumann.com/\n\nStraumann conducts research with leading universities, and manufactures dental implants and a host of other products in the dental industry. Because technological advancements are changing dentistry fundamentally, Straumann offers a broad range of products and solutions for both conventional treatment and digital workflows, including guided surgery, intraoral scanning, and CAD/CAM restorations.\n\nSTERIS PLC (NYSE: STE)\n\nTotal Revenue: $2.78B USD\n\nMarket Cap: $13.86B USD\n\nR&D Spend: $63.03M USD\n\nEmployee Size: 12,000\n\nWebsite: https://www.steris.com/\n\nSteris PLC provides infection prevention and other procedural products and services. The company operates through four segments: health care products, which offers infection prevention and procedural solutions for health care providers, including capital equipment and related maintenance, installation services, and consumables; health care specialty services, which provides a range of specialty services for health care providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities; and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.\n\nFREE RESOURCE: Click here to download a PDF chart of the top 100 medical device companies in the world.\n\nHOLOGIC INC. (NASDAQ: HOLX)\n\nTotal Revenue: $3.21B USD\n\nMarket Cap: $12.85B USD\n\nR&D Spend: $218.7M USD\n\nEmployee Size: 6,252\n\nWebsite: http://www.hologic.com/\n\nHologic Inc., incorporated on January 18, 1990, is a developer, manufacturer, and supplier of diagnostics products, medical imaging systems, and surgical products, with an emphasis on women's health. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company sells and services its products through a combination of direct sales and service personnel and a network of independent distributors and sales representatives.\n\nWATERS CORPORATION (NYSE: WAT)\n\nTotal Revenue: $2.41B USD\n\nMarket Cap: $12.6B USD\n\nR&D Spend: $143M USD\n\nEmployee Size: 7,200\n\nWebsite: http://www.waters.com/\n\nWaters Corp., a publicly traded corporation (NYSE: WAT) headquartered in Milford, Massachusetts, holds leading positions worldwide in complementary analytical technologies — liquid chromatography, mass spectrometry, rheometry, and microcalorimetry.\n\nSpecifically, the company designs, manufactures, sells, and services ultra-performance liquid chromatography (UPLC), high-performance liquid chromatography (HPLC), chromatography columns and chemistry products, mass spectrometry (MS) systems, thermal analysis, and rheometry instruments.\n\nWaters Corp. operates in two divisions: Waters Division and TA Instruments.\n\nWEST PHARMACEUTICAL SERVICES INC. (NYSE: WST)\n\nTotal Revenue: $1.72B USD\n\nMarket Cap: $11.55BB USD\n\nR&D Spend: $40.3M USD\n\nEmployee Size: 7,400\n\nWebsite: https://www.westpharma.com/\n\nWest Pharmaceutical Services Inc., incorporated on July 27, 1923, is a manufacturer of packaging components and delivery systems for injectable drugs and health care products. The company's products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.\n\nVARIAN MEDICAL SYSTEMS INC. (NYSE: VAR)\n\nTotal Revenue: $2.61B USD\n\nMarket Cap: $11.47B USD\n\nR&D Spend: $246M USD\n\nEmployee Size: 10,062\n\nWebsite: http://www.varian.com/\n\nVarian Medical Systems Inc., incorporated on January 22, 1976, is a manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy medical devices. The company also offers Varian Particle Therapy (VPT) and owns the Ginzton Technology Center (GTC). Its VPT business develops, designs, manufactures, sells, and services products and systems for delivering proton therapy, another form of external beam radiotherapy using proton beams for the treatment of cancer.\n\nDENTSPLY SIRONA INC. (NASDAQ: XRAY)\n\nTotal Revenue: $3.98B USD\n\nMarket Cap: $11.04B USD\n\nR&D Spend: $160.5M USD\n\nEmployee Size: 16,400\n\nWebsite: https://www.dentsplysirona.com\n\nDENTSPLY SIRONA Inc., incorporated on February 15, 1983, is a manufacturer of professional dental products and technologies. The company develops, manufactures, and markets solutions like dental and oral health products, as well as other consumable medical devices. The company operates through two segments: dental and health care consumables, and medical technology. The dental industry encompasses the diagnosis, treatment, and prevention of disease and ailments of the teeth, gums, and supporting bone. The company's principal dental product categories are dental consumable products, dental laboratory products, dental specialty products, and dental equipment. Additionally, the company's consumable medical device products are used for urological and surgical applications.\n\nMASIMO CORPORATION (NASDAQ: MASI)\n\nTotal Revenue: $858M USD\n\nMarket Cap: $9.5BUSD\n\nR&D Spend: $76.9M USD\n\nEmployee Size: 1,500\n\nWebsite: http://www.masimo.com/\n\nMasimo Corporation, incorporated on May 7, 1996, is a medical technology company that develops, manufactures, and markets a range of noninvasive patient-monitoring technologies. The company's business is measure-through motion and low perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include noninvasive monitoring of blood constituents with an optical signature, optical organ oximetry monitoring, and more.\n\nSARTORIUS STEDIM BIOTECH S.A. (ETR: SRT)\n\nTotal Revenue: €1.93B EUR\n\nMarket Cap: €6.87B EUR\n\nR&D Spend: €95.6M EUR\n\nEmployee Size: 9,016\n\nWebsite: https://www.sartorius.com\n\nSartorius Stedim Biotech SA is a German-based international provider of laboratory and process technologies and equipment. The company covers the segments of biotechnology and mechatronics. Sartorius provides services that help customers implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The company’s customers are from the biotech, pharma, and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia, and America and also has sales offices and local representatives in more than 110 countries. The company operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd., and Wave Biotech AG, among others.\n\nFISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (NZE: FPH)\n\nTotal Revenue: $1.07B NZD\n\nMarket Cap: $15.28B NZD\n\nR&D Spend: $428.2M NZD\n\nEmployee Size: 4,500\n\nWebsite: https://www.fphcare.com/\n\nFisher & Paykel Healthcare Corporation Limited designs, manufactures, and markets medical device products and systems for use in respiratory care, acute care, and the treatment of obstructive sleep apnea. The company's segments include New Zealand, which includes all activities controlled by entities or employees based in New Zealand; North America, which includes all activities controlled by entities or employees based in the United States and Canada; Europe, which includes all activities controlled by entities or employees based in the United Kingdom, France, Germany, Sweden, Turkey, and Russia; and Asia-Pacific, which includes all activities controlled by entities or employees based in Australia, Japan, India, China, South Korea, Taiwan, and Hong Kong. Its products include respiratory humidifiers, single-use and reusable chambers and breathing circuits, infant resuscitators, infant warmers, and accessories. In addition, the company offers hardware and consumables.\n\nCOCHLEAR LIMITED (ASX: COH)\n\nTotal Revenue: $1.24B AUD\n\nMarket Cap: $12B AUD\n\nR&D Spend: $184.4M AUD\n\nEmployee Size: 4,000\n\nWebsite: https://www.cochlear.com/\n\nCochlear Limited is engaged in providing implantable hearing solutions. The company's implant systems comprise an implant, which is inserted during surgery, and an external sound processor. The company operates through three segments, based on geography: EMEA, Asia/Pacific, and the Americas. The Americas includes Canada, Latin America, and the United States. EMEA includes Europe, the Middle East, and Africa. Asia/Pacific includes Australasia and Asia. The company's products and solutions include cochlear implants, such as Nucleus 6 and Aqua+; bone conduction implants, such as Baha Attract and Baha Connect; acoustic implant solutions, such as the Cochlear Carina System, the Cochlear MET System, and the Cochlear Codacs System, and others. The company sells its products in over 100 countries.\n\nABIOMED INC. (NASDAQ: ABMD)\n\nTotal Revenue: $769M USD\n\nMarket Cap: $6.99B USD\n\nR&D Spend: $94M USD\n\nEmployee Size: 1,350\n\nWebsite: http://www.abiomed.com/\n\nAbiomed (NASDAQ: ABMD) is a leading provider of medical devices that provide circulatory support. Their products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. CEO, chairman, and president Michael R. Minogue has focused the company’s efforts on developing groundbreaking technologies designed to improve patient outcomes focused on native heart recovery. Founded in 1981 to develop the world’s first artificial heart, Abiomed has remained dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.\n\nASAHI INTECC CO. LTD. (TYO: 7747)\n\nTotal Revenue: ¥50.12B JPY\n\nMarket Cap: ¥734.13B JPY\n\nR&D Spend: ¥12.3B JPY\n\nEmployee Size: 7,810\n\nWebsite: http://www.asahi-intecc.co.jp/\n\nAsahi Intecc Co. Ltd. was founded in Japan in 1976. The company specializes in making ultrafine stainless steel ropes for use in catheter treatment. The company also manufactures products for cardiovascular treatments. The company is headquartered in Nagoya and has six branches worldwide.\n\nHILL-ROM HOLDINGS INC. (NYSE: HRC)\n\nTotal Revenue: $2.91B USD\n\nMarket Cap: $6.74B USD\n\nR&D Spend: $139.5M USD\n\nEmployee Size: 10,000\n\nWebsite: http://www.hill-rom.com/\n\nHill-Rom Holdings Inc., incorporated on August 7, 1969, is a global medical technology company. The company partners with health care providers across care settings by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: advancing mobility; wound care and prevention; patient monitoring and diagnostics; surgical safety and efficiency; and respiratory health. Its segments include Patient Support Systems, Front Line Care, and Surgical Solutions.\n\nAMPLIFON SPA (BIT: AMP)\n\nTotal Revenue: €1.37B EUR\n\nMarket Cap: €5.46B EUR\n\nR&D Spend: None\n\nEmployee Size: 16,000\n\nWebsite: https://www.amplifon.com/\n\nAmplifon SpA is an Italy-based company engaged in the hearing systems industry. It distributes, adjusts, and personalizes hearing aids. It offers a generation of invisible hearing amplifiers, tiny electronic instruments that receive, process, and amplify sounds that are then transmitted to the ear, thanks to the instruments’ clear and precise amplification process. They are able to meet needs because they address a wide range of problems stemming from slight to serious hearing loss. The hearing aids ensure that listening quality is consistent as they adapt to different sound environments. The company operates through the following brands: Sonus, Miracle-Ear, Beter Horen, and Dialogue, among others.\n\nHAEMONETICS CORPORATION (NYSE: HAE)\n\nTotal Revenue: $967M USD\n\nMarket Cap: $5.56B USD\n\nR&D Spend: $35.7M USD\n\nEmployee Size: 3,216\n\nWebsite: https://www.haemonetics.com/\n\nHaemonetics Corporation, incorporated on August 29, 1985, is a health care company. The company provides various products to customers involved in the processing, handling, and analysis of blood. The company's segments include Japan, EMEA, North America Plasma, and the rest of the world. It provides plasma collection systems and software, enabling plasma fractionators to make pharmaceuticals. It provides analytical devices for measuring hemostasis, which enable health care providers to manage their patients' bleeding risk. Haemonetics makes blood processing systems and software, which tracks blood components.\n\nSHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LTD. (HKG: 1066)\n\nTotal Revenue: ¥8.8B CNY\n\nMarket Cap: $5.02B USD\n\nR&D Spend: ¥311.6M CNY\n\nEmployee Size: 9,562\n\nWebsite: http://en.weigaogroup.com/\n\nShandong Weigao Group Medical Polymer Co. Ltd. is principally engaged in the research and development, production, and sale of single-use medical devices. The company sells products under brands Jierui and Wego Ortho. The company operates through three business segments. The Single-Use Medical Device Products segment is engaged in the production and sale of single-use consumables, such as infusion sets, syringes, blood transfusion sets, and blood bags. The Orthopedic Products segment is engaged in the production and sale of orthopedic products. The Blood Purification Products segment is engaged in the production and sale of blood purification products and related medical equipment.\n\nINSULET CORPORATION (NASDAQ: PODD)\n\nTotal Revenue: $738M USD\n\nMarket Cap: $10.85 USD\n\nR&D Spend: $129.7M USD\n\nEmployee Size: 1,350\n\nWebsite: http://www.insulet.com/\n\nInsulet Corporation, incorporated on July 20, 2000, is engaged in the development, manufacture, and sale of the Omnipod Insulin Management System (the Omnipod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System eliminates the need for a bulky pump, tubing, and separate blood glucose meter; provide for virtually pain-free automated cannula insertion; communicate wirelessly; and integrate a blood glucose meter.\n\nGLOBUS MEDICAL INC. (NYSE: GMED)\n\nTotal Revenue: $785.4M USD\n\nMarket Cap: $4.7B USD\n\nR&D Spend: $60M USD\n\nEmployee Size: 1,800\n\nWebsite: http://www.globusmedical.com/\n\nGlobus Medical Inc., incorporated on March 3, 2003, is a medical device company. The company is focused on developing products for patients with musculoskeletal disorders. It is focused on products to treat patients with spine disorders. The company's products fall under categories including Innovative Fusion and Disruptive Technologies. The products in the Innovative Fusion category include fusion products to treat spinal disorders for the entire spine, and they can be used in various surgical approaches. The Disruptive Technologies category represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders.\n\nGETINGE AB (CPH: GETI-B)\n\nTotal Revenue: 24.2B SEK\n\nMarket Cap: $4.68B USD\n\nR&D Spend: 1.25B SEK\n\nEmployee Size: 10,515\n\nWebsite: https://www.getinge.com\n\nGetinge AB is a global medical technology company, founded in Sweden in 1904. The firm provides equipment and systems within health care and life sciences. Getinge is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within health care and life sciences. The company was organized into three distinct business areas: Infection Control (Getinge), Extended Care (ArjoHuntleigh) and Medical Systems (Maquet), but it was announced in March 2017 that the company would unify its brands under the Getinge name moving forward.\n\nTANDEM DIABETES CARE INC. (NASDAQ: TNDM)\n\nTotal Revenue: $183.9M USD\n\nMarket Cap: $4.64B USD\n\nR&D Spend: $8.7M USD\n\nEmployee Size: 643\n\nWebsite: https://www.tandemdiabetes.com/\n\nTandem Diabetes Care Inc., incorporated on January 7, 2008, is a medical device company. The company is engaged in designing, developing, and commercializing products for people with insulin-dependent diabetes. The company manufactures and sells more than three insulin pump products in the United States that are designed to address the insulin-dependent diabetes market, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex), and t:slim G4 Insulin Delivery System (t:slim G4). The company's technology platform features Micro-Delivery Technology, a miniaturized pumping mechanism that draws insulin from a flexible bag within the pump's cartridge rather than relying on a syringe-and-plunger mechanism.\n\nINTEGRA LIFESCIENCES HOLDINGS CORPORATION (NASDAQ: IART)\n\nTotal Revenue: $1.47B USD\n\nMarket Cap: $4.44B USD\n\nR&D Spend: $77.9M USD\n\nEmployee Size: 4,500\n\nWebsite: https://www.integralife.com/\n\nIntegra LifeSciences Holdings Corporation, incorporated on June 19, 1989, is a medical technology company. The company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. The company's segments include Specialty Surgical Solutions and Orthopedics and Tissue Technologies. The company's products are used in neurosurgery, extremity reconstruction, orthopedics, and general surgery.\n\nINOGEN INC. (NASDAQ: INGN)\n\nTotal Revenue: $361.9M USD\n\nMarket Cap: $4.311B USD\n\nR&D Spend: $3.62M USD\n\nEmployee Size: 1,020\n\nWebsite: https://www.inogen.com/\n\nInogen Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators in the United States and internationally. The company’s oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It offers Inogen One, a portable device that concentrates the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; and related accessories.\n\nNEVRO CORP. (NYSE: NVRO)\n\nTotal Revenue: $387.2M USD\n\nMarket Cap: $4.25B USD\n\nR&D Spend: $48.45M USD\n\nEmployee Size: 804\n\nWebsite: https://www.nevro.com/\n\nNevro Corp., incorporated on October 4, 2006, is a global medical device company. The company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia.\n\nICU MEDICAL INC. (NASDAQ: ICUI)\n\nTotal Revenue: $1.4B USD\n\nMarket Cap: $4.15B USD\n\nR&D Spend: $52.8M USD\n\nEmployee Size: 8,100\n\nWebsite: http://www.icumed.com/\n\nICU Medical Inc., incorporated on January 9, 1992, is engaged in the development, manufacture, and sale of medical devices used in infusion therapy, oncology, and critical care applications. The company's product line includes needle-free connection devices; custom infusion sets; closed-system transfer devices (CSTD) for the handling of hazardous drugs; advanced sensor catheters; needle-free closed blood sampling systems; disposable pressure transducer systems; and hemodynamic monitoring systems. As of December 31, 2016, its products were used in acute care hospitals and ambulatory clinics in more than 65 countries throughout the world.\n\nWRIGHT MEDICAL GROUP N.V. (NASDAQ: WMGI)\n\nTotal Revenue: $836M USD\n\nMarket Cap: $3.91B USD\n\nR&D Spend: $59.1M USD\n\nEmployee Size: 2,894\n\nWebsite: http://www.wright.com/\n\nWright Medical Group N.V. is a medical device company with segments including U.S. Lower Extremities & Biologics, U.S. Upper Extremities, and International Extremities & Biologics. As of 2019, the company markets hundreds of products in over 50 countries worldwide. Wright Medical Group makes biologics and sport medicine products, as well as products for upper and lower extremities. Wright Medical Group acquired Cartiva Inc. for $435 million USD in 2018.\n\nMICROPORT SCIENTIFIC CORPORATION (HKG: 0853)\n\nTotal Revenue: $669.49M USD\n\nMarket Cap: $3.828B HKD\n\nR&D Spend: $104.8M USD\n\nEmployee Size: 5,000\n\nWebsite: http://www.microport.com/\n\nMicroPort Scientific Corporation is a Hong Kong-based investment holding company principally engaged in the manufacture and sale of medical products. The company operates through seven segments. The Orthopedics Devices segment researches, develops, manufactures, and sells orthopedics devices. The Cardiovascular Devices segment researches, develops, manufactures, and sells cardiovascular devices, such as drug-eluting stents. The Endovascular Devices segment researches, develops, manufactures, and sells endovascular devices. The Electrophysiology Devices segment researches, develops, manufactures, and sells electrophysiology devices. The Neurovascular Devices segment researches, develops, manufactures, and sells neurovascular devices. The Surgical Management segment researches, develops, manufactures, and sells surgical devices. The Diabetes Care and Endocrine Management segment researches, develops, manufactures, and sells devices related to diabetes mellitus.\n\nNUVASIVE (NASDAQ: NUVA)\n\nTotal Revenue: $1.1B USD\n\nMarket Cap: $3.42B USD\n\nR&D Spend: $61M USD\n\nEmployee Size: 2,600\n\nWebsite: http://www.nuvasive.com/\n\nNuVasive Inc., incorporated on July 21, 1997, is a medical device company. The company focuses on developing minimally disruptive surgical products and procedurally integrated solutions for spine surgery. The company's product portfolio focuses on applications for spinal-fusion surgery, including biologics used to aid in the spinal-fusion process. The company's principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery (MAS).\n\nCONMED CORPORATION (NYSE: CONMED)\n\nTotal Revenue: $859.63M\n\nMarket Cap: $2.78B USD\n\nR&D Spend: $42.1M USD\n\nEmployee Size: 3,100\n\nWebsite: http://www.conmed.com/\n\nCONMED Corporation, incorporated on February 10, 1970, is a medical technology company. The company is, engaged on a global basis, in the development, manufacture, and sale of surgical devices and related equipment. The company provides surgical devices and equipment for minimally invasive procedures. The company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The company's product lines consist of orthopedic surgery, general surgery, and surgical visualization. The company's products are distributed domestically directly to thousands of hospitals, surgery centers, and other health care institutions, as well as through medical specialty distributors.\n\nGERRESHEIMER AG (ETR: GXI)\n\nTotal Revenue: €1.34B EUR\n\nMarket Cap: €2.13B EUR\n\nR&D Spend: None\n\nEmployee Size: 9,872\n\nWebsite: https://www.gerresheimer.com/\n\nGerresheimer AG is a Germany-based company that is active in the pharmaceuticals and health care industries. The company operates through two business segments: Plastics and Devices, and Primary Packaging Glass. The Plastics and Devices segment produces standard and customized products for drug delivery, such as insulin pens, inhalers, and prefillable syringes. The Primary Packaging Glass segment focuses on the production of packaging of glass for medicines and cosmetics, such as pharmaceutical jars, ampoules, injection vials, cartridges, perfume flacons, and cream jars, as well as glass containers for the food and beverage industry. The company operates approximately 40 production facilities in Europe, North America, South America, and Asia.\n\nMERIT MEDICAL SYSTEMS (NASDAQ: MMSI)\n\nTotal Revenue: $882.7M USD\n\nMarket Cap: $2.04B USD\n\nR&D Spend: $59.53M USD\n\nEmployee Size: 5,783\n\nWebsite: https://www.merit.com/\n\nMerit Medical Systems Inc., incorporated on July 28, 1987, is a manufacturer and marketer of disposable medical devices used in a range of interventional, diagnostic, and therapeutic medical procedures. The company operates in two segments: cardiovascular and endoscopy. The cardiovascular segment consists of cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease, and other nonvascular diseases, and includes embolotherapeutic, cardiac rhythm management (CRM), electrophysiology (EP), and interventional oncology and spine devices. Its endoscopy segment consists of gastroenterology and pulmonology medical devices, which assist in the palliative treatment of expanding esophageal, tracheobronchial, and biliary strictures caused by malignant tumors.\n\nPRESTIGE BRANDS HOLDINGS (NYSE: PBH)\n\nTotal Revenue: $975.77M USD\n\nMarket Cap: $1.93B USD\n\nR&D Spend: None\n\nEmployee Size: 530\n\nWebsite: http://prestigebrands.com/\n\nPrestige Brands Holdings Inc., incorporated on June 24, 2004, is engaged in the marketing, sales, and distribution of over-the-counter health care products to mass merchandisers; drug stores; supermarkets; and club, convenience, and dollar stores in North America (the United States and Canada), in Australia, and in certain other international markets. The company operates through two segments: North American over-the-counter (OTC) health care and International OTC health care.\n\nYPSOMED HOLDING AG (SWX: YPSN)\n\nTotal Revenue: 453.8M CHF\n\nMarket Cap: 1.78B CHF\n\nR&D Spend: 41.9M CHF\n\nEmployee Size: 1,604\n\nWebsite: https://www.ypsomed.com/\n\nYpsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The company develops and manufactures injection systems for custom-made self-administration, and it markets pen needles for the treatment of diabetes, growth disorders, or infertility. The company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the company's Ypsomed Delivery Systems (YDS) offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pumps to diabetes patients and to doctors and health insurance providers. The company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor and has sales and distribution network across Europe.\n\nGLAUKOS CORPORATION (NYSE: GKOS)\n\nTotal Revenue: $236.98M USD\n\nMarket Cap: $1.61B USD\n\nR&D Spend: $68.3M USD\n\nEmployee Size: 600\n\nWebsite: http://www.glaukos.com/\n\nGlaukos Corporation, incorporated on July 14, 1998, is an ophthalmic medical technology company. The company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It has developed the microinvasive glaucoma surgery (MIGS) to serve as an alternative to the traditional glaucoma treatment and management paradigm. It offers iStent, a MIGS device. The iStent is a micro-bypass stent inserted through a small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra, and the iDose. The iStent Inject includes two stents preloaded in an autoinjection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods to lower intraocular pressure in glaucoma patients.\n\nATRICURE INC (NASDAQ: ATRC)\n\nTotal Revenue: $201.6M USD\n\nMarket Cap: $1.57B USD\n\nR&D Spend: $34.7M USD\n\nEmployee Size: 620\n\nWebsite: http://www.atricure.com/\n\nAtriCure Inc., incorporated on October 31, 2000, is an atrial fibrillation (AFib) solutions company. The company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue, as well as systems designed for the exclusion of the left atrial appendage. The company’s Isolator Synergy Ablation System was designed for the treatment of persistent and long-standing persistent forms of AFib in patients undergoing certain open concomitant procedures. The company offers various minimally invasive ablation devices and access tools to facilitate less invasive cardiac and thoracic surgery.\n\nSTAAR SURGICAL COMPANY (NASDAQ: STAA)\n\nTotal Revenue: $150.2M USD\n\nMarket Cap: $1.42B USD\n\nR&D Spend: $25.2M USD\n\nEmployee Size: 475\n\nWebsite: http://www.staar.com/\n\nSTAAR Surgical Company (STAAR), incorporated on April 3, 1986, designs, develops, manufactures, and sells implantable lenses for the eye, as well as delivery systems used to deliver the lenses into the eye. The company operates in the ophthalmic surgical market segment. The company's principal products are intraocular lenses (IOLs) used in cataract surgery and implantable collamer lenses (ICLs) used in refractive surgery. The company makes lenses used in corrective or refractive surgery across the world and makes lenses for use in surgery that treats cataracts.\n\nCARDIOVASCULAR SYSTEMS INC. (NASDAQ: CSII)\n\nTotal Revenue: $217M USD\n\nMarket Cap: $1.39B USD\n\nR&D Spend: $26.8M USD\n\nEmployee Size: 652\n\nWebsite: http://www.csi360.com/\n\nCardiovascular Systems Inc., incorporated on December 6, 2000, is a medical technology company. The company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee.\n\nARJO AB (STO: ARJO-B)\n\nTotal Revenue: 8.21B SEK\n\nMarket Cap: 13.89B SEK\n\nR&D Spend: 201M SEK\n\nEmployee Size: 6,123\n\nWebsite: https://www.arjo.com/int/\n\nArjo AB is a medical device company that manufactures medical devices, services, and solutions aimed to improve quality of life for people with reduced mobility and age-related health issues. The company sells products in over 100 countries throughout North America and Western Europe, and other regions. The company is headquartered in Malmö, Sweden.\n\nATRION CORPORATION (NASDAQ: ATRI)\n\nTotal Revenue: $152.4M USD\n\nMarket Cap: $1.22B USD\n\nR&D Spend: $5.5M\n\nEmployee Size: 570\n\nWebsite: http://www.atrioncorp.com/\n\nAtrion Corporation (Atrion), incorporated on December 30, 1996, is engaged in developing and manufacturing products primarily for medical applications. The company's medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold, and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter, and other applications in areas such as anesthesia and oncology.\n\nPAUL HARTMANN AG (OTC: PLHNF)\n\nTotal Revenue: €2.12B EUR\n\nMarket Cap: €1.1B EUR\n\nR&D Spend: €478.86M EUR\n\nEmployee Size: 11,027\n\nWebsite: https://www.hartmann.info/en-corp\n\nPaul Hartmann AG is headquartered in Heidenheim, Germany. The company manufactures personal hygiene and medical products and operates in Europe, Asia, North America, South America, Africa, and Australia. The company operates through four segments, which are Wound Management, Incontinence Management, Infection Management, and Other Group Activities.\n\nLUMINEX CORP. (NASDAQ: LMNX)\n\nTotal Revenue: $315.8M USD\n\nMarket Cap: $1.19B USD\n\nR&D Spend: $47.2M USD\n\nEmployee Size: 1,141\n\nWebsite: https://www.luminexcorp.com/\n\nLuminex Corporation, incorporated on June 19, 1998, develops, manufactures, and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical, and life sciences industries. The company's products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine, and infectious disease segments.\n\nMESA LABORATORIES INC. (NASDAQ: MLAB)\n\nTotal Revenue: $103.13M USD\n\nMarket Cap: $1.1B USD\n\nR&D Spend: $3.5M USD\n\nEmployee Size: 366\n\nWebsite: http://www.mesalabs.com/\n\nMesa Laboratories Inc., incorporated on March 26, 1982, is focused primarily on quality control products and services. The company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators, and Cold Chain. The Instruments division designs, manufactures, and markets quality control instruments and disposable products utilized in connection with the health care, pharmaceutical, food and beverage, medical device, industrial hygiene, environmental air sampling, and semiconductor industries.\n\nCRYOLIFE INC. (NYSE: CRY)\n\nTotal Revenue: $262.8M USD\n\nMarket Cap: $990M USD\n\nR&D Spend: $23.6M USD\n\nEmployee Size: 1,100\n\nWebsite: http://www.cryolife.com/\n\nCryoLife’s mission is to restore patients’ health and quality of life by delivering innovative technologies. CryoLife is one of the world’s leading contemporary medical device companies, providing preserved human tissues for cardiac and vascular surgeries; mechanical heart valves for aortic or mitral valve replacement; surgical adhesives and sealants; cardiac lasers for treatment of refractory angina; and state-of-the-art technology and surgical training in adult and pediatric cardiovascular surgery.\n\nSince its inception in 1984, it is estimated that CryoLife’s products and tissues have been implanted in over 1 million patients worldwide.\n\nNATUS MEDICAL INC. (NASDAQ: BABY)\n\nTotal Revenue: $495.1M USD\n\nMarket Cap: $940M USD\n\nR&D Spend: $58.73M USD\n\nEmployee Size: 1,484\n\nWebsite: https://natus.com\n\nNatus Medical Incorporated (Natus) offers medical equipment, software, supplies, and services for the diagnosis, monitoring, and treatment of impairments and disorders affecting newborns, nerves, muscles, balance, mobility, hearing, and the brain. Natus is organized into three strategic business units: neuro, newborn care, and otometrics.\n\nBIOTAGE AB (CPH: BIOT)\n\nTotal Revenue: $1.1B SEK\n\nMarket Cap: $7.739B SEK\n\nR&D Spend: $78.6M SEK\n\nEmployee Size: 464\n\nWebsite: http://www.biotage.com/\n\nBiotage AB is a Sweden-based company that develops and sells systems, consumables, and services in the field of life sciences. Its customers include companies within the pharmaceutical and biotechnology industries, companies within the food industry, and institutions within academia. The company offers systems and services within three areas: analytical chemistry, organic chemistry, and industrial resins. Biotage’s offering within analytical chemistry consists of consumables with related applications to extract selected substances from various types of samples. The company’s offering within organic chemistry includes products for pharmaceutical development based on both small molecules and peptides. The company’s offering related to industrial resins is composed of polymer-based resins and research services that lead to the development and manufacture of polymer-based materials.\n\nINTERSECT ENT INC. (NASDAQ: XENT)\n\nTotal Revenue: $108.47M USD\n\nMarket Cap: $730M USD\n\nR&D Spend: $19.26M USD\n\nEmployee Size: 393\n\nWebsite: http://www.intersectent.com/\n\nIntersect ENT Inc., incorporated on October 6, 2003, is a commercial-stage drug-device company. The company develops drugs for patients with ear, nose, and throat (ENT) conditions. The company has developed a drug-releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The company's commercial products are the PROPEL and PROPEL Mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis.\n\nORTHOFIX INTERNATIONAL N.V. (NYSE: OFIX)\n\nTotal Revenue: $453M USD\n\nMarket Cap: $700M USD\n\nR&D Spend: $33.21M USD\n\nEmployee Size: 954\n\nWebsite: http://www.orthofix.com/\n\nOrthofix International N.V. (Orthofix), incorporated on October 19, 1987, is a global medical device company. The company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates through four segments: BioStim, Biologics, Extremity Fixation, and Spine Fixation. The company provides an array of implants designed for use primarily in cervical, thoracic, and lumbar fusion surgeries. These implants are made of either metal or a thermoplastic compound called Polyetheretherketones (PEEK). The company also provides an array of implants designed for use primarily in cervical, thoracic, and lumbar fusion surgeries.\n\nADVANCED MEDICAL SOLUTIONS GROUP PLC (LON: AMS)\n\nTotal Revenue: £102.6M GBP\n\nMarket Cap: £545.82 GBP\n\nR&D Spend: £3.07M GBP\n\nEmployee Size: 600\n\nWebsite: http://www.admedsol.com/\n\nAdvanced Medical Solutions Group PLC, together with its subsidiaries, designs, develops, manufactures, and distributes products for the advanced wound care, surgical, and wound-closure markets worldwide. It operates through two segments: Branded and OEM. The company offers natural and synthetic polymers for use in advanced wound-care dressings under the ActivHeal brand; medical adhesives for closing and sealing tissue under the LiquiBand brand; and sutures and hemostats for the medical device market under the RESORBA brand.\n\nCONSORT MEDICAL PLC (LON: CSRT)\n\nTotal Revenue: £305.1M GBP\n\nMarket Cap: £502.1M GBP\n\nR&D Spend: £7.9 GBP\n\nEmployee Size: 2,000\n\nWebsite: http://www.consortmedical.com/\n\nConsort Medical PLC is a contract development and manufacturing organization (CDMO). The company's principal activities include the design, development, and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The company operates through two segments: Bespak and Aesica. Bespak's core business is the manufacture of inhaled drug delivery devices for life sciences partners, and its operations are based in the United Kingdom. The Aesica business manufactures and sells active pharmaceutical ingredients (API), formulated pharmaceutical products, and packaging services to the pharmaceutical industry, and its operations are based in the United Kingdom and Europe. It offers its services to customers, such as pharmaceutical companies. Its device products include metered-dose inhalers, dry powder devices, actuators, dose counters, disposable autoinjectors, nasal devices, and point-of-care diagnostics devices.\n\nLEMAITRE VASCULAR INC. (NASDAQ: LMAT)\n\nTotal Revenue: $105.56M USD\n\nMarket Cap: $580M USD\n\nR&D Spend: $8.1M USD\n\nEmployee Size: 483\n\nWebsite: http://www.lemaitre.com/\n\nLeMaitre Vascular Inc., incorporated on June 15, 1998, is a provider of medical devices for the treatment of peripheral vascular disease. The company develops, manufactures, and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales, and technical support of medical devices and implants. The company's product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts, and powered phlebectomy devices.\n\nAXOGEN INC. (NASDAQ: AXGN)\n\nTotal Revenue: $106.71M USD\n\nMarket Cap: $470M USD\n\nR&D Spend: $17.5M USD\n\nEmployee Size: 297\n\nWebsite: http://www.axogeninc.com/\n\nAxogen Inc., incorporated on June 20, 1977, offers surgical solutions for peripheral nerve injuries. The company provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, and Avive Soft Tissue Membrane. Along with these core surgical products, the company also offers the Axotouch Two-Point Discriminator, and the AcroVal Neurosensory and Motor Testing System. These evaluation and measurement tools assist health care professionals in detecting changes in sensation; assessing return of sensory, grip, and pinch function; evaluating treatment interventions; and providing feedback about nerve function to patients.\n\nANGIODYNAMICS INC. (NASDAQ: ANGO)\n\nTotal Revenue: $344.28M USD\n\nMarket Cap: $440M USD\n\nR&D Spend: $25.45M USD\n\nEmployee Size: 1,145\n\nWebsite: http://www.angiodynamics.com/\n\nAngioDynamics Inc., incorporated on July 30, 1992, designs, manufactures, and sells a range of medical, surgical, and diagnostic devices used by professional health care providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The company's devices are used in minimally invasive, image-guided procedures. The company offers products within three product groupings: Peripheral Vascular, Vascular Access, and Oncology/Surgery.\n\nOWENS & MINOR INC. (NYSE: OMI)\n\nTotal Revenue: $9.83B USD\n\nMarket Cap: $380M USD\n\nR&D Spend: None\n\nEmployee Size: 17,900\n\nWebsite: https://www.owens-minor.com/\n\nOwens & Minor Inc. is a global health care logistics company founded and headquartered in Virginia. Owens & Minor was founded in 1882 and now operates on four continents. In 2018, the company acquired Halyard Health Inc. for $710 million, the largest Owens & Minor acquisition to date. Owens & Minor has been a Fortune 500 company for 25 years, most recently ranked at 317.\n\nORASURE TECHNOLOGIES INC. (NASDAQ: OSUR)\n\nTotal Revenue: $181.74M USD\n\nMarket Cap: $380M USD\n\nR&D Spend:$16.3M USD\n\nEmployee Size: 347\n\nWebsite: http://www.orasure.com\n\nOraSure Technologies Inc. (OraSure), incorporated on May 5, 2000, is involved in the development, manufacture, marketing, and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture, and sale of diagnostic products, specimen collection devices, and medical devices. DNAG consists primarily of the development, manufacture, and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing.\n\nCUTERA INC. (NASDAQ: CUTR)\n\nTotal Revenue: $162.7M USD\n\nMarket Cap: $330M USD\n\nR&D Spend: $14.3M USD\n\nEmployee Size: 402\n\nWebsite: http://www.cutera.com/\n\nCutera Inc., incorporated on August 10, 1998, is a medical device company. The company is engaged in the design, development, manufacture, marketing, and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The company offers products based on product platforms, such as Enlighten, Excel HR, TruSculpt, Excel V, and Xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers. Each of its laser and other energy-based platforms consists of one or more handpieces and a console that incorporates control system software, high voltage electronics, a universal graphical user interface, and a laser or another energy-based module.\n\nUTAH MEDICAL PRODUCTS INC. (NASDAQ: UTMD)\n\nTotal Revenue: $41.9M USD\n\nMarket Cap: $320M USD\n\nR&D Spend: $454K USD\n\nEmployee Size: 173\n\nWebsite: http://www.utahmed.com/\n\nUtah Medical Products Inc. (UTMD), incorporated on April 21, 1978, is engaged in the business of producing medical devices that are disposable and are for hospital use. The company's product categories include labor and delivery, obstetrics; neonatal intensive care; gynecology/urology/electrosurgery; and blood pressure monitoring. UTMD markets a range of medical devices used in care areas, such as the neonatal intensive care unit (NICU), the labor and delivery (L&D) department, and the women's health center in hospitals, as well as products sold to outpatient clinics and physicians’ offices. Domestically, UTMD's medical devices are sold directly to clinical end-user facilities by the company's own direct sales representatives and independent manufacturers' representatives.\n\nRTI SURGICAL INC. (NASDAQ: RTIX)\n\nTotal Revenue: $290.9M USD\n\nMarket Cap: $280M USD\n\nR&D Spend: $14.4M USD\n\nEmployee Size: 891\n\nWebsite: http://www.rtix.com/\n\nRTI Surgical Inc. is a global surgical implant company providing surgeons with biologic, metal, and synthetic implants. It operates through the following business lines: Spine, Sports Medicine and Orthopedics, Surgical Specialties, Cardiothoracic, International, and Global Commercial. The Spine business line designs, manufactures, and distributes surgical implants, instruments, and biologics used in the treatment of conditions affecting the spine caused by degenerative conditions, deformities, or traumatic injury.\n\nVIEWRAY INC. (ASX: VRAY)\n\nTotal Revenue: $81M USD\n\nMarket Cap: $280M USD\n\nR&D Spend: $4.01M USD\n\nEmployee Size: 221\n\nWebsite: http://www.viewray.com/\n\nViewRay Inc., incorporated in 2013, through its subsidiary ViewRay Technologies Inc., designs, manufactures, and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery, and the company's software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered.\n\nBIOLIFE SOLUTIONS INC. (NASDAQ: BLFS)\n\nTotal Revenue: $19.7M USD\n\nMarket Cap: $280M USD\n\nR&D Spend: $315K USD\n\nEmployee Size:54\n\nWebsite: https://biolifesolutions.com/\n\nBioLife Solutions Inc. (BioLife), incorporated on March 25, 1998, is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage, and cryopreservation freeze media and a related cloud-hosted biologistics cold chain management application for shippers.\n\nINVACARE CORPORATION (NYSE: IVC)\n\nTotal Revenue: $972.34M USD\n\nMarket Cap: $270M USD\n\nR&D Spend: $17.3M USD\n\nEmployee Size: 4,200\n\nWebsite: http://www.invacare.com/\n\nInvacare Corporation, incorporated on March 23, 1971, is a manufacturer and distributor of medical equipment used in nonacute care settings. The company designs, manufactures, and distributes medical devices that help people move, breathe, rest, and perform essential hygiene. The company's geographical segments are Europe, North America, and Asia/Pacific. The company provides medical device solutions for congenital, acquired, and degenerative ailments.\n\nSEASPINE HOLDINGS CORPORATION (NASDAQ: SPNE)\n\nTotal Revenue: $143M USD\n\nMarket Cap: $270M USD\n\nR&D Spend: $3.2M USD\n\nEmployee Size: 386\n\nWebsite: http://www.seaspine.com/\n\nSeaSpine Holdings Corporation, incorporated on February 12, 2015, is a medical technology company. The company is focused on the design, development, and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. The company operates through the development, manufacture, and marketing of orthobiologics and spinal-fusion hardware segment. The company has a portfolio of orthobiologics and spinal-fusion hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures in the lumbar, thoracic, and cervical spine.\n\nIRADIMED CORPORATION (NASDAQ: IRMD)\n\nTotal Revenue: $30.4M USD\n\nMarket Cap: $270M USD\n\nR&D Spend: $1.5M USD\n\nEmployee Size: 95\n\nWebsite: http://www.iradimed.com/\n\nIRadimed Corporation (IRADIMED), incorporated on April 8, 2014, develops, manufactures, markets, and distributes magnetic resonance imaging (MRI)-compatible products and provides nonmagnetic intravenous (IV) infusion pump systems. The company operates through the development, manufacture, and sale of MRI-compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures. The company's MRidium MRI-compatible IV infusion pump system has been designed with nonferrous parts, a nonmagnetic ultrasonic motor, and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. Each system consists of an MRidium MRI-compatible IV infusion pump, a nonmagnetic mobile stand, and disposable IV tubing sets.\n\nTRISTEL PLC (LON: TSTL)\n\nTotal Revenue: £26.17M GBP\n\nMarket Cap: £193.6M GBP\n\nR&D Spend: None\n\nEmployee Size: 111\n\nWebsite: http://www.tristel.com/\n\nTristel PLC is a United Kingdom-based manufacturer of infection prevention and contamination control products. The company's technology is a chlorine dioxide formulation. The company operates through three segments: human health care, animal health care, and contamination control. The human health care segment is engaged in the manufacture, development, and sale of infection control and hygiene products, which include products that are used primarily for infection control in hospitals; the segment’s products are marketed under the brand Tristel. The Animal Healthcare segment relates to the manufacture and sale of disinfection and cleaning products for veterinary and animal welfare sectors; the segment’s products are marketed under the brand Anistel. The Contamination Control segment addresses the pharmaceutical and personal care product manufacturing industries.\n\nGENMARK DIAGNOSTICS INC. (NASDAQ: GNMK)\n\nTotal Revenue: $70.75M USD\n\nMarket Cap: $200M USD\n\nR&D Spend: $27.93M USD\n\nEmployee Size: 477\n\nWebsite: http://www.genmarkdx.com/\n\nGenMark Diagnostics Inc., incorporated on February 12, 2010, is a molecular diagnostics company. The company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. The company develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests, which run on its XT-8 instrument: the Respiratory Viral Panel; the Cystic Fibrosis Genotyping Test; the Warfarin Sensitivity Test; and the Thrombophilia Risk Test.\n\nNEMAURA MEDICAL INC. (NASDAQ: NMRD)\n\nTotal Revenue: None\n\nMarket Cap: $159.2M USD\n\nR&D Spend: $2.29B USD\n\nEmployee Size: 10\n\nWebsite: http://www.nemauramedical.com/\n\nNemaura Medical Inc. is a medical technology company that discovers, develops, and commercializes specialty medical devices. It provides SugarBEAT, a noninvasive continuous glucose monitoring device for use by persons with type 1 and type 2 diabetes, as well as for screening prediabetic patients.\n\nFONAR CORPORATION (NASDAQ: FONR)\n\nTotal Revenue: $81.5M USD\n\nMarket Cap: $130M USD\n\nR&D Spend: $1.7M USD\n\nEmployee Size: 525\n\nWebsite: http://www.fonar.com/\n\nFonar Corporation (Fonar), incorporated on July 17, 1978, is engaged in the business of designing, manufacturing, selling, and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, injuries, and other medical conditions. The company operates its business through two segments: Medical Equipment, and Physician Management and Diagnostic Services. Its Medical Equipment segment is conducted through Fonar. Its Physician Management and Diagnostic Services segment is conducted through its subsidiary Health Management Company of America (HMCA).\n\nHARVARD BIOSCIENCE INC. (NASDAQ: HBRO)\n\nTotal Revenue: $120.77M USD\n\nMarket Cap: $110M USD\n\nR&D Spend:$11M USD\n\nEmployee Size: 547\n\nWebsite: http://www.harvardbioscience.com/\n\nHarvard Bioscience Inc., incorporated on October 8, 2000, is a developer, manufacturer, and marketer of a range of scientific instruments, systems, and lab consumables used for basic research, drug discovery, and clinical and environmental testing. The company's products are sold to thousands of researchers in over 100 countries through its global sales organization, websites, and catalogs and through distributors. The company's product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI, and CMA Microdialysis. The company's products consist of instruments, consumables, and systems that are made up of various individual products.\n\nCHINA GRAND PHARMACEUTICAL AND HEALTHCARE HOLDINGS LIMITED\n\nTotal Revenue: $5.95B HKD\n\nMarket Cap: $310.8M HKD\n\nR&D Spend: $137.4M HKD\n\nEmployee Size: 8,0006\n\nWebsite: http://www.chinagrandpharm.com/\n\nChina Grand Pharmaceutical and Healthcare Holdings Limited is a Hong Kong-based investment holding company principally engaged in the manufacture of pharmaceuticals. The main businesses of the company include the research and development, manufacture, and sale of pharmaceutical products, medical products, chemical products, and health care products. The products of the company include preparations, raw materials, medical devices, and health care products, as well as agricultural and fine chemicals. It mainly focuses on ophthalmic, cardiovascular, and antibacterial products.\n\nTRANSENTERIX INC. (NYSE: TRXC)\n\nTotal Revenue: $24.1M USD\n\nMarket Cap: $29.43M USD\n\nR&D Spend: $21.8M USD\n\nEmployee Size: 189\n\nWebsite: https://transenterix.com/\n\nTransEnterix Inc., incorporated on August 19, 1988, is a medical device company. The company is focused on the development and commercialization of the ALF-X Surgical Robotic System (the ALF-X System), a multiport robotic system; and the SurgiBot System, a single-port, laparoscopic surgical platform. The company also develops and manufactures laparoscopic surgical instruments such as scissors, graspers, clip appliers, and suction and irrigation instruments used in abdominal surgery.\n\nThe company's ALF-X System is a multiport robotic surgery system, which allows multiple robotic arms to control instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera through eye movement.\n\nENDOLOGIX INC. (NASDAQ: ELGX)\n\nTotal Revenue: $156.4M USD\n\nMarket Cap: $20M USD\n\nR&D Spend: $20.7M USD\n\nEmployee Size: 528\n\nWebsite: http://www.endologix.com/\n\nEndologix Inc., incorporated on June 2, 1993, is engaged in developing, manufacturing, marketing, and selling medical devices for the treatment of aortic disorders. The company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms: either traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through blood-flow lumens.\n\nB. BRAUN MELSUNGEN AG (PRIVATELY HELD)\n\nTotal Revenue: €6.9B EUR\n\nMarket Cap: Privately Held\n\nR&D Spend: €318M EUR\n\nEmployee Size: 62,855\n\nWebsite: http://www.bbraun.com/\n\nBraun is one of the world's leading providers and manufacturers of health care solutions today. Every service that B. Braun provides incorporates the entirety of the company’s knowledge and skills, the company's deep understanding of users' needs, and extensive expertise. With its constantly growing portfolio of effective medical care solutions, B. Braun makes a substantial contribution toward protecting and improving people's health. In total, the B. Braun product range comprises 5,000 different products, 95 percent of which are manufactured by the company.\n\nFREE RESOURCE: Click here to download a PDF chart of the top 100 medical device companies in the world.\n\nLooking for an all-in-one QMS solution to advance the success of your in-market devices and integrates your quality processes with product development efforts? Click here to take a quick tour of Greenlight Guru's Medical Device QMS software →"
    }
}